[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346427-105":59,"doc-detail-346427-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","from-in-silico-qsar-modeling-to-in-vitro-mtt-assay-experimental-validation-of-novel-upar-leads-for-triple-negative-breast-cancer-tnbc-and-skin-cancer","From in-silico QSAR modeling to in-vitro MTT assay - experimental validation of novel uPAR leads for triple-negative breast cancer (TNBC) and skin cancer","","uPAR is a key driver of tumor invasion, epithelial–mesenchymal transition, and metastatic spread in aggressive cancers, including triple-negative breast cancer (MDA-MB-231) and skin cancer (A431). The study integrates computational QSAR modeling with experimental MTT cytotoxicity testing to identify new small-molecule uPAR inhibitors. A QSAR model built on 816 diverse antagonists achieved strong internal and external predictivity, followed by virtual screening of ChemDiv. Docking and MD simulation supported binding stability and ligand-dependent electrostatic/steric complementarity, while MTT assays quantified potency and dose-dependent apoptotic morphology, motivating further optimization toward preclinical evaluation.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-in-silico-qsar-modeling-to-in-vitro-mtt-assay-experimental-validation-of-novel-upar-leads-for-triple-negative-breast-cancer-tnbc-and-skin-cancer/346427/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-in-silico-qsar-modeling-to-in-vitro-mtt-assay-experimental-validation-of-novel-upar-leads-for-triple-negative-breast-cancer-tnbc-and-skin-cancer/346427.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-15","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why is uPAR considered an important therapeutic target?","Question",{"text":112,"@type":113},"uPAR regulates tumor invasion, epithelial–mesenchymal transition, extracellular matrix degradation, and metastatic dissemination. Its overexpression and central role make it promising yet underutilized for therapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were lead candidates identified in this study?",{"text":117,"@type":113},"A comprehensive QSAR model was developed from 816 uPAR antagonists, then used to virtually screen the ChemDiv database. Two lead candidates emerged: D685-0061 and C878-1660.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the in vitro MTT assays show about the two leads?",{"text":121,"@type":113},"Both ligands showed cytotoxicity quantified by MTT assays, with D685-0061 being more potent in MDA-MB-231 cells (IC₅₀ 21.34 µM) and C878-1660 more effective in A431 cells (IC₅₀ 18.93 µM).",{"name":123,"@type":110,"acceptedAnswer":124},"What support did docking and MD simulation provide?",{"text":125,"@type":113},"Molecular docking indicated C878-1660 forms favorable hydrophobic and hydrogen-bond interactions, while MD simulation showed C878-1660 generated a stable complex (RMSD ~1.5 Å over 500 ns) compared with D685-0061.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},346427,1790168129,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":24,"preview_urls":150},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nFrom in-silicoQSAR modeling to in-vitro MTT assay: experimental validation of novel uPAR leads for triple-negative breast cancer (TNBC) and skin cancer  \nHarshal Badukle1, Rahul D. Jawarkar1􀀍, Umang Shah2, Somdutta Chaudhary3, Abdullah Yahya Abdullah Alzahrani4, Abdul Samad5, Sami A. Al-Hussain6, AamalA. Al-Mutairi6 & Magdi E.A. Zaki6  \nThe urokinase plasminogen activator receptor (uPAR) is crucial in processes such as tumor invasion, epithelial–mesenchymal transition, and the metastatic spread of aggressive cancers, including triplenegative breast cancer (MDA-MB-231) and skin cancer (A431). Due to its overexpression and key role in regulating extracellular matrix degradation and cell migration, uPAR stands out as a promising but underutilized therapeutic target. This research combines computational modeling with experimental validation to discover new small-molecule inhibitors of uPAR. A comprehensive QSAR model was developed utilizing 816 structurally diverse uPAR antagonists, resulting in high internal predictivity (R² = 0.84) and external validation accuracy (R²_ext = 0.8014). Key molecular descriptors that influence inhibition, such as com_Nminus_ 2A, lipo_S_ 1Ac, fHC3B, and fdonringC7A, have been identified as critical factors in determining electrostatic and steric complementarity. The virtual screening of the ChemDiv database using QSAR methods identified two lead candidates: D685-0061 and C878-1660 . Molecular docking analysis demonstrated that C878-1660 interacts with uPAR through advantageous hydrophobic and hydrogen-bond interactions, while D685-0061 displayed relatively weaker binding affinity. The ligand, C878-1660 formed a stable complex (RMSD ~ 1.5 Å over 500 ns), whereas D685- 0061 showed higher flexibility (RMSD ~ 2.7 Å). The cytotoxic effects of both ligands were quantified using in vitro MTT assays. D685-0061 demonstrated a higher potency in MDA-MB-231 cells, with an  \nIC₅₀ of 21.34 µM, in contrast to C878-1660, which had an IC₅₀ of 81.82 µM. Conversely, C878-1660 showed greater effectiveness inA431 cells, exhibiting an IC₅₀ of 18.93 µM compared to D685-0061’s IC₅₀ of 28.34 µM. The observed apoptotic morphology was consistent with a dose-dependent relationship, supporting these findings. This study presents a thorough computational-experimental pipeline that identifies two promising lead molecules targeting uPAR and provides mechanistic insights into their binding and cytotoxic profiles. The gathered evidence substantiates the need for further optimization and progression toward preclinical evaluation for uPAR-driven cancers.  \nKeywords Urokinase plasminogen activator receptor (uPAR), Cancer, QSAR, Molecular docking, MD simulation, PCA, Free energy landscape, MTT assay  \nGlobal cancer statistics for 2023 reveal an estimated 20.0 million new cancer cases and 9.7 million cancer deaths worldwide. This data highlights a persistent increase in the disease burden, influenced by factors such  \n1Department of Pharmaceutical Chemistry, Dr. Rajendra Gode Institute of Pharmacy, Ghatkheda, university mardi Road, Amravati 444602, M. S, India. 2Department of Pharmaceutical Chemistry, Ramanbhai Patel College of Pharmacy, CHARUSAT Campus, 388421 Changa, Gujarat, India. 3Department of Pharmaceutical Chemistry, P. E. S. Modern College of Pharmacy, Nigdi, Pune, India. 4Department of Chemistry, Faculty of Science, King Khalid University, Abha 61413, Saudi Arabia. 5Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tishk International University, Erbil 44001, Iraq. 6Department of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 11623, Saudi Arabia. 􀀍 email: [rahuljawarkar@gmail.com](rahuljawarkar@gmail.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nas population aging and lifestyle-related risks. Breast cancer is the most frequently diagnosed malignancy worldwide, h","cbCaidCnBS37jGJb","https://ap.wps.com/l/cbCaidCnBS37jGJb","pdf",7181950,42,"English","# Introduction\n# QSAR Modeling and Virtual Screening\n# Molecular Docking and MD Simulation\n# In Vitro MTT Cytotoxicity Assays\n# Findings and Implications","[{\"question\":\"Why is uPAR considered an important therapeutic target?\",\"answer\":\"uPAR regulates tumor invasion, epithelial–mesenchymal transition, extracellular matrix degradation, and metastatic dissemination. Its overexpression and central role make it promising yet underutilized for therapy.\"},{\"question\":\"How were lead candidates identified in this study?\",\"answer\":\"A comprehensive QSAR model was developed from 816 uPAR antagonists, then used to virtually screen the ChemDiv database. Two lead candidates emerged: D685-0061 and C878-1660.\"},{\"question\":\"What did the in vitro MTT assays show about the two leads?\",\"answer\":\"Both ligands showed cytotoxicity quantified by MTT assays, with D685-0061 being more potent in MDA-MB-231 cells (IC₅₀ 21.34 µM) and C878-1660 more effective in A431 cells (IC₅₀ 18.93 µM).\"},{\"question\":\"What support did docking and MD simulation provide?\",\"answer\":\"Molecular docking indicated C878-1660 forms favorable hydrophobic and hydrogen-bond interactions, while MD simulation showed C878-1660 generated a stable complex (RMSD ~1.5 Å over 500 ns) compared with D685-0061.\"}]","From in-silico QSAR modeling to in-vitro MTT assay - experimental validation of novel uPAR leads for triple-negative breast cancer (TNBC) and skin cancer | PDF",1790061414,106,[151,155,159,163,167],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c86122e3764a5021fe03f746f25b40e5.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c687509518d1758bd0e9e80422c488d8.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99bbaac3c5d1cc64fa6f576b118cae3d.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/00e7cd65505687e352175b48fc58d287.webp",980,1287,{"page_no":24,"url":168,"width":169,"height":170},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7978c9f8974cd45f75ebd8bbb244be7f.webp",979,1286]